4/A: Verrica Pharmaceuticals CEO Ted White Receives 150,000 Restricted Stock Units Following First Commercial Sale of VP-102; Amends Previous Filing to Correctly Report RSU Award Size

Verrica Pharmaceuticals CEO Ted White received 150,000 restricted stock units (RSUs) that vested upon the first commercial sale of VP-102, and an amendment was filed to correct a misreporting in the initial Form 4 regarding the total number of RSUs awarded.

Summary

• On August 24, 2023, Verrica Pharmaceuticals CEO Ted White received 150,000 restricted stock units (RSUs).
• These RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023.
• The remaining 50% of the RSUs will vest on August 24, 2024, the one-year anniversary of the first sale.
• An amendment to the original Form 4 filed on August 28, 2023, was made to correct the number of RSUs awarded.
• The initial filing unintentionally misreported the number of shares, reporting only the vested portion instead of the full award size.
• After the transaction, White beneficially owns 278,789 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the vesting of RSUs is tied to a positive event (first commercial sale), and the correction of the filing indicates transparency. However, it's a routine disclosure.

Positives

• The vesting of RSUs for the CEO is tied to the commercial success of VP-102, aligning management's interests with shareholders.
• The correction of the initial filing demonstrates transparency and attention to detail.

Future Outlook

The remaining 50% of the RSUs will vest on August 24, 2024, contingent on continued employment.

Industry Context

This type of equity compensation is common in the pharmaceutical industry to incentivize executives and align their interests with the success of the company's products.

Comparison to Industry Standards

• Equity compensation packages for CEOs in the pharmaceutical industry typically include a mix of stock options, restricted stock units, and performance-based awards.
• The vesting schedule tied to the commercial sale of VP-102 is a common practice to incentivize the successful launch and market penetration of new drugs.
• Comparing Verrica's executive compensation structure to companies like Castle Biosciences or Novan, which are also focused on dermatology, could provide further context.

Stakeholder Impact

• The vesting of RSUs aligns the CEO's interests with shareholders, incentivizing him to drive the company's success.
• Employees may view the vesting of RSUs as a positive sign of the company's progress.

Key Dates